Up­dat­ed: Will the UK’s triple-pronged ap­proach ease pric­ing, reg­u­la­to­ry and fi­nan­cial bot­tle­necks?

Oc­to­ber and No­vem­ber were crit­i­cal months in shap­ing the fu­ture of the UK’s bio­phar­ma sec­tor. Af­ter sev­er­al years of macro­eco­nom­ic chal­lenges, the gov­ern­ment un­veiled a bun­dle of new drug pric­ing, reg­u­la­to­ry and fi­nan­cial mea­sures in the fourth quar­ter aimed at in­creas­ing the at­trac­tive­ness of its health­care sys­tem to both in­dus­try and in­vestors at lo­cal and glob­al lev­els.

For starters, the UK re­cent­ly re­freshed its ap­proach to drug pric­ing in a bid to save its NHS mon­ey while al­so boost­ing the com­pet­i­tive­ness of its drugs mar­ket. The UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency (MHRA) has al­so made moves to ad­dress how long com­pa­nies wait for clin­i­cal tri­al au­tho­riza­tions. And, just last month, chan­cel­lor Je­re­my Hunt un­veiled a pack­age of new eco­nom­ic com­mit­ments aimed at “un­lock­ing growth and pro­duc­tiv­i­ty” in the home­grown life sci­ence space.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER